KERRI GRIFFIN: Open Payments
NPI 1861007957 · ENTERPRISE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,208 in 53 payments from 17 companies in 2025. Trend: 2023 $877 · 2024 $1,157 · 2025 $1,208
Food & beverage: $1,205Education: $3
| Company | Payments | Amount |
|---|---|---|
| Vifor Pharma, Inc. | 7 | $162 |
| Medtronic, Inc. | 4 | $151 |
| AstraZeneca Pharmaceuticals LP | 7 | $137 |
| Travere Therapeutics, Inc. | 6 | $100 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $86 |
| OPKO Pharmaceuticals, LLC | 5 | $82 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $82 |
| Fresenius USA Marketing, Inc. | 3 | $71 |
| SCPHARMACEUTICALS INC. | 3 | $66 |
| Novartis Pharmaceuticals Corporation | 2 | $63 |
Products named: Veltassa, SYMPLICITY G3, FARXIGA, Kerendia, RAYALDEE, JARDIANCE, VELPHORO, FUROSCIX.
Industry payments across AL — which companies pay providers there.
